|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||Commercial Rights|
|eryaspase (GRASPA® (1))||Asparaginase||PDAC 2L|
Pancreatic cancer is a particularly aggressive type of cancer, with a five-year survival rate of less than 10%. It is also one of the fastest growing cancer indications. With approximately 150,000 new cases diagnosed each year in Europe and worldwide, pancreatic cancer represents an important unmet medical need.
In 2017, we reported positive Phase 2b clinical trial data of eryaspase in combination with chemotherapy for metastatic pancreatic cancer in second line treatment. The open-label, randomized, multi-center clinical trial in 141 patients met its co-primary endpoints and demonstrated significant improvement in both overall survival (OS) and progression-free survival (PFS). The hazard ratio for overall survival in the entire patient population was 0.60 (nominal p-value = 0.009), meaning that treatment with eryaspase reduced the risk of death rate by 40% compared to treatment with chemotherapy alone.
This clinical trial represents the first time an asparaginase-based therapy has been reported to have a survival benefit in a solid tumor indication. This trial forms the basis for our strategy to explore the further development of eryaspase for the treatment of pancreatic cancer and other solid tumor indications.